Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis
Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.
- What were the key updates for treatment in the 2022 ATS Guidelines and what additional information is needed in future iterations?
- How do you see the guidelines changing as novel agents enter the treatment landscape?
- There were no FDA-approved therapies for IPF/PPF prior to anti-fibrotic agents. How have these therapy options altered treatment of the disease?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
